Materiały źródłowe

• #1 Invasive Lobular Carcinoma — Cancer Stat Facts

  https://seer.cancer.gov/statfacts/html/ilc.html

  Invasive lobular carcinoma (ILC), also known as lobular breast cancer, accounts for 15% of all new breast cancer diagnoses. ILC is the second most common histological type of breast cancer, with approximately 47,500 lobular breast cancer diagnoses each year in the United States. Lobular breast cancer impacts more women than do cancers of the kidney, brain, pancreas, liver or ovaries. In 2025, it is estimated that there are 316,950 new cases of female breast cancer in the United States. Among these newly diagnosed breast cancer cases, 10%-15% are diagnosed as invasive lobular carcinoma. […] 68% of all new lobular diagnoses are in women over the age of 60, while 59% of non-lobular diagnoses occur in women over the age of 60. 89% of all new cases of lobular breast cancer are HR+/HER-2-, while 67% of non-lobular carcinomas are HR+/HER-2-.

• #2 Invasive Lobular Carcinoma: Symptoms, Treatment, Research | BCRF

  https://www.bcrf.org/about-breast-cancer/invasive-lobular-carcinoma/

  Invasive lobular carcinoma, also referred to as invasive lobular breast cancer (ILC) or simply lobular carcinoma/breast cancer, is the second most common type of breast cancer after invasive ductal carcinoma (IDC). Lobular breast cancer represents 10 to 15 percent of all invasive breast cancers. Over the past two decades, incidence rates of lobular carcinoma have increased. An estimated 43,000 new cases of invasive lobular breast cancer are diagnosed every year. Despite its prevalence, our understanding of the unique biology of lobular breast cancer is still emerging. […] The diffuse growth pattern of lobular carcinoma can make diagnosis particularly challenging. In addition, these breast cancers are also more likely to be multi-focal (occurring in more than one location) or bilateral (occurring in both breasts), which complicates accurate screening, detection, and treatment.

• #3 Invasive Lobular Carcinoma — Cancer Stat Facts

  https://seer.cancer.gov/statfacts/html/ilc.html

  Invasive lobular carcinoma (ILC), also known as lobular breast cancer, accounts for 15% of all new breast cancer diagnoses. ILC is the second most common histological type of breast cancer, with approximately 47,500 lobular breast cancer diagnoses each year in the United States. Lobular breast cancer impacts more women than do cancers of the kidney, brain, pancreas, liver or ovaries. In 2025, it is estimated that there are 316,950 new cases of female breast cancer in the United States. Among these newly diagnosed breast cancer cases, 10%-15% are diagnosed as invasive lobular carcinoma. […] 68% of all new lobular diagnoses are in women over the age of 60, while 59% of non-lobular diagnoses occur in women over the age of 60. 89% of all new cases of lobular breast cancer are HR+/HER-2-, while 67% of non-lobular carcinomas are HR+/HER-2-.

• #4 Invasive Lobular Carcinoma: Symptoms, Treatment, Research | BCRF

  https://www.bcrf.org/about-breast-cancer/invasive-lobular-carcinoma/

  Invasive lobular carcinoma, also referred to as invasive lobular breast cancer (ILC) or simply lobular carcinoma/breast cancer, is the second most common type of breast cancer after invasive ductal carcinoma (IDC). Lobular breast cancer represents 10 to 15 percent of all invasive breast cancers. Over the past two decades, incidence rates of lobular carcinoma have increased. An estimated 43,000 new cases of invasive lobular breast cancer are diagnosed every year. Despite its prevalence, our understanding of the unique biology of lobular breast cancer is still emerging. […] The diffuse growth pattern of lobular carcinoma can make diagnosis particularly challenging. In addition, these breast cancers are also more likely to be multi-focal (occurring in more than one location) or bilateral (occurring in both breasts), which complicates accurate screening, detection, and treatment.

• #5 Invasive Lobular Carcinoma — Cancer Stat Facts

  https://seer.cancer.gov/statfacts/html/ilc.html

  Invasive lobular carcinoma (ILC), also known as lobular breast cancer, accounts for 15% of all new breast cancer diagnoses. ILC is the second most common histological type of breast cancer, with approximately 47,500 lobular breast cancer diagnoses each year in the United States. Lobular breast cancer impacts more women than do cancers of the kidney, brain, pancreas, liver or ovaries. In 2025, it is estimated that there are 316,950 new cases of female breast cancer in the United States. Among these newly diagnosed breast cancer cases, 10%-15% are diagnosed as invasive lobular carcinoma. […] 68% of all new lobular diagnoses are in women over the age of 60, while 59% of non-lobular diagnoses occur in women over the age of 60. 89% of all new cases of lobular breast cancer are HR+/HER-2-, while 67% of non-lobular carcinomas are HR+/HER-2-.

• #6 Invasive Lobular Carcinoma — Cancer Stat Facts

  https://seer.cancer.gov/statfacts/html/ilc.html

  Invasive lobular carcinoma (ILC), also known as lobular breast cancer, accounts for 15% of all new breast cancer diagnoses. ILC is the second most common histological type of breast cancer, with approximately 47,500 lobular breast cancer diagnoses each year in the United States. Lobular breast cancer impacts more women than do cancers of the kidney, brain, pancreas, liver or ovaries. In 2025, it is estimated that there are 316,950 new cases of female breast cancer in the United States. Among these newly diagnosed breast cancer cases, 10%-15% are diagnosed as invasive lobular carcinoma. […] 68% of all new lobular diagnoses are in women over the age of 60, while 59% of non-lobular diagnoses occur in women over the age of 60. 89% of all new cases of lobular breast cancer are HR+/HER-2-, while 67% of non-lobular carcinomas are HR+/HER-2-.

• #7 Breast Cancer: Practice Essentials, Background, Anatomy

  https://emedicine.medscape.com/article/1947145-overview

  In the United States, approximately 316,950 new cases of invasive breast cancer in women are predicted to occur in 2025, along with 2800 cases in men. Among US women in 2025, in addition to invasive breast cancer, 59,080 new cases of ductal carcinoma in situ (DCIS) are expected to be diagnosed. […] The incidence of breast cancer in the United States increased rapidly from 1980 to 1987, largely as a consequence of the widespread use of mammography screening, which led to increased detection of asymptomatic small breast tumors. After 1987, the increase in overall rates of invasive breast cancers slowed significantly, specifically among White women aged 50 years or older. Incidence over this period of time varied dramatically by histologic type. Common ductal carcinomas increased modestly from 1987 to 1999, whereas invasive lobular and mixed ductal-lobular carcinomas increased dramatically during this time period.

• #8 Invasive Lobular Carcinoma: Symptoms, Treatment, Research | BCRF

  https://www.bcrf.org/about-breast-cancer/invasive-lobular-carcinoma/

  Invasive lobular carcinoma, also referred to as invasive lobular breast cancer (ILC) or simply lobular carcinoma/breast cancer, is the second most common type of breast cancer after invasive ductal carcinoma (IDC). Lobular breast cancer represents 10 to 15 percent of all invasive breast cancers. Over the past two decades, incidence rates of lobular carcinoma have increased. An estimated 43,000 new cases of invasive lobular breast cancer are diagnosed every year. Despite its prevalence, our understanding of the unique biology of lobular breast cancer is still emerging. […] The diffuse growth pattern of lobular carcinoma can make diagnosis particularly challenging. In addition, these breast cancers are also more likely to be multi-focal (occurring in more than one location) or bilateral (occurring in both breasts), which complicates accurate screening, detection, and treatment.

• #9 Invasive Lobular Cancer (ILC) Melbourne, VIC | Radiotherapy Melbourne, VIC

  https://www.melbournebreastcancersurgery.com.au/breast-cancer/invasive-lobular-cancer-ilc.html

  Invasive lobular breast cancer (ILC) is the second most common type of breast cancer, behind invasive ductal carcinoma (IDC) of no special type (NST), accounting for around 10-15% of breast cancers. […] Over the past two decades, incidence rates of lobular carcinoma have increased, mainly among the post-menopausal population, and is likely to be the result of improved diagnostic techniques and the use of hormone replacement therapy. […] According to the American Cancer Society, about two-thirds of women diagnosed with invasive lobular carcinoma are age 55 or older. […] The characteristic insidious infiltrative process makes ILC difficult to identify radiographically, and the extent of disease challenging to define. […] Specifically, ILC has a tendency to be underestimated by conventional breast imaging, and a higher likelihood to be multifocal/multicentric, which complicates accurate screening, detection, and treatment.

• #10 Invasive Lobular Carcinoma — Cancer Stat Facts

  https://seer.cancer.gov/statfacts/html/ilc.html

  Invasive lobular carcinoma (ILC), also known as lobular breast cancer, accounts for 15% of all new breast cancer diagnoses. ILC is the second most common histological type of breast cancer, with approximately 47,500 lobular breast cancer diagnoses each year in the United States. Lobular breast cancer impacts more women than do cancers of the kidney, brain, pancreas, liver or ovaries. In 2025, it is estimated that there are 316,950 new cases of female breast cancer in the United States. Among these newly diagnosed breast cancer cases, 10%-15% are diagnosed as invasive lobular carcinoma. […] 68% of all new lobular diagnoses are in women over the age of 60, while 59% of non-lobular diagnoses occur in women over the age of 60. 89% of all new cases of lobular breast cancer are HR+/HER-2-, while 67% of non-lobular carcinomas are HR+/HER-2-.

• #11 Invasive Lobular Cancer (ILC) Melbourne, VIC | Radiotherapy Melbourne, VIC

  https://www.melbournebreastcancersurgery.com.au/breast-cancer/invasive-lobular-cancer-ilc.html

  Invasive lobular breast cancer (ILC) is the second most common type of breast cancer, behind invasive ductal carcinoma (IDC) of no special type (NST), accounting for around 10-15% of breast cancers. […] Over the past two decades, incidence rates of lobular carcinoma have increased, mainly among the post-menopausal population, and is likely to be the result of improved diagnostic techniques and the use of hormone replacement therapy. […] According to the American Cancer Society, about two-thirds of women diagnosed with invasive lobular carcinoma are age 55 or older. […] The characteristic insidious infiltrative process makes ILC difficult to identify radiographically, and the extent of disease challenging to define. […] Specifically, ILC has a tendency to be underestimated by conventional breast imaging, and a higher likelihood to be multifocal/multicentric, which complicates accurate screening, detection, and treatment.

• #12 Lobular Breast Carcinoma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK554578/

  Invasive lobular carcinoma is the second most common histologic form of breast cancer, representing 5% to 15% of all invasive breast cancers. […] The incidence of breast cancer according to GLOBOCAN 2018 in the world is 46.3 per 100,000 inhabitants, while in the United States the incidence is 84.9 cases per 100,000 inhabitants, and a death rate of 12.7 deaths per 100,000 – which is the second leading cause for death among all cancers after lung cancer. […] Lobular carcinoma of the breast represents approximately 5% to 15% of all invasive breast cancers, with an average age at diagnosis three years greater than invasive ductal carcinoma. […] In recent studies, they found that lobular tumors are more likely to be Luminal A between 45% to 51%, these, in turn, are less frequent in young ( 50 years) and Black women, and are larger, low grade, with less frequency of TP53 pathway defects and with a tendency to be diagnosed in late stages.

• #13 Lobular Breast Carcinoma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK554578/

  Invasive lobular carcinoma is the second most common histologic form of breast cancer, representing 5% to 15% of all invasive breast cancers. […] The incidence of breast cancer according to GLOBOCAN 2018 in the world is 46.3 per 100,000 inhabitants, while in the United States the incidence is 84.9 cases per 100,000 inhabitants, and a death rate of 12.7 deaths per 100,000 – which is the second leading cause for death among all cancers after lung cancer. […] Lobular carcinoma of the breast represents approximately 5% to 15% of all invasive breast cancers, with an average age at diagnosis three years greater than invasive ductal carcinoma. […] In recent studies, they found that lobular tumors are more likely to be Luminal A between 45% to 51%, these, in turn, are less frequent in young ( 50 years) and Black women, and are larger, low grade, with less frequency of TP53 pathway defects and with a tendency to be diagnosed in late stages.

• #14 Pathology Outlines – Invasive lobular carcinoma classic

  https://www.pathologyoutlines.com/topic/breastmalignantlobularclassic.html

  Epidemiology […] – Comprises about 10% of invasive breast carcinomas (Breast Cancer Res 2015;17:37) […] – Most common special subtype of invasive breast carcinoma (Br J Cancer 2005;93:1046) […] – Only comprises 1% of male breast carcinomas (Breast Cancer (Dove Med Press) 2017;9:337) […] – Mean age of diagnosis is 63.4 years, higher than that for invasive breast carcinoma of no special type (Br J Cancer 2005;93:1046) […] – Endogenous (lower parity, younger age at menarche and later menopause) and exogenous (hormone replacement therapy and oral contraceptives) estrogen exposure increases risk (Breast Cancer Res 2015;17:37) […] – Alcohol consumption and obesity are risk factors, which may be mediated by increased levels of circulating estrogen […] – 60% lifetime risk in women with hereditary diffuse gastric cancer syndrome (germline CDH1 mutation) (J Med Genet 2010;47:436) […] – Under represented in breast carcinomas of BRCA1 carriers (2.2%) and similar proportion BRCA2 carriers (8.4%) (Cancer Epidemiol Biomarkers Prev 2012;21:134)

• #15 Invasive lobular carcinoma of the… preview & related info | Mendeley

  https://www.mendeley.com/catalogue/5a521389-8909-3088-86b7-1f0e471de361/

  Male breast cancer is rare, comprising only 1% of all mammary cancers; invasive ductal carcinoma is by far the commonest subtype in both men and women. […] Though lobular breast cancer is the second most common subtype seen in women, such cancers are extremely uncommon in men, and this is likely related to the lack of lobular development in the male breast. […] A comprehensive analysis of the National Cancer Institutes Surveillance, Epidemiology, and End Results Data 19732013 leading to an exploration of the pathogenesis, epidemiology, clinical presentation, diagnosis, tumor characteristics, and management of lobular breast carcinoma in men is also discussed. […] Lobular subtype of breast cancer remains an enigmatic elusive disease that needs additional research to unravel its overall pathogenesis and molecular profile to provide insight for improved therapeutic management options.

• #16 Clinicopathological characteristics and survival outcomes of invasive lobular carcinoma in different races | Oncotarget

  https://www.oncotarget.com/article/19396/

  To investigate the clinicopathological characteristics and to determine whether there is a differential effect of race and examine survival outcomes according to race, 18,295 breast invasive lobular carcinoma (ILC) patients were identified in the Surveillance, Epidemiology, and End Result (SEER) database, which includes White patients (n=15,936), Black patients (n=1,451) and patients of other races (including American Indians/Alaskan Natives and Asian/Pacific Islanders) (n=908). […] The five-year overall survival (OS) and five-year breast cancer specific survival (BCSS) were worst in the Black patients among these patients (85.5%, 76.0% and 87.7%, P0.01; 91.1%, 84.4% and 91.6%, P0.01). […] Among these patients, the Black patients had the worst survival outcomes in five-year OS and BCSS outcomes (HR=1.35, 95% confidence interval (CI) :1.20-1.51, P0.01; HR=1.39, 95%CI:1.21-1.61, P0.01, respectively). […] In conclusion, this study revealed that the Black patients had worse five-year OS and BCSS than White and other race patients.

• #17 Case: Invasive Lobular Carcinoma – Radiology | UCLA Health

  https://www.uclahealth.org/departments/radiology/education/breast-imaging-teaching-resources/cases/case-invasive-lobular-carcinoma

  Invasive lobular carcinoma (ILC) is the second most common invasive breast cancer accounting for 5-15% of invasive breast cancers behind invasive ductal carcinoma (IDC). ILC is typically seen in post-menopausal women, peaking at age 50-601. It is more common in white individuals but has a higher mortality rate in African American individuals as they have a higher predisposition to have grade 3 ILC. Additionally, with the increased rate of post-menopausal hormone therapy, the incidence of ILC has increased over the last 20 years2. […] The clinical features of ILC are far more varying and less defined versus its counter-part IDC. Patients with ILC may present with a vague palpable area of breast tissue that appears more thickened or swollen compared to the remaining breast tissue, nipple changes, skin dimpling, or asymmetric breast size1. Given its vague clinical and radiographic features, ILC is more difficult to detect and ultimately manage, resulting in 67% of these patients presenting with metastatic disease1. Compared to IDC, ILC is far more likely to metastasize to the peritoneum or retroperitoneum, gastro-intestinal tract, urogenital tract, leptomeninges, and myocardium. The metastatic rate to the liver, bone, and pleura is comparable to that of IDC3. Additionally, ILC has a greater rate of involving the contralateral breast resulting in bilateral cancer when compared to IDC; the bilateral involvement is reported at 20-29%4.

• #18 Lobular Research | UCSF Department of Surgery

  https://lobularbreastcancer.ucsf.edu/lobular-research-overview

  Invasive lobular carcinoma (ILC) is known to be a hormone receptor positive and HER2 receptor negative breast cancer. Our analysis showed that the characteristics of early stage (I-III) ILC can vary by socioeconomic status (SES, which we measured using education and income). In this cohort of over 200,000 patients with ILC in the National Cancer Database, we found that low SES was associated with fewer hormone positive and higher-grade tumors. […] We are interested in understanding the distribution and the clinical significance of ER/PR hormone receptor positivity in early-stage ILC. Overall, we know that ILC is typically regarded as strongly ER and PR positive and there is very little data that exists evaluating the spectrum of hormone receptor positivity in ILC. […] A recent analysis of the SEER database showed that racial/ethnic identity is associated with worse outcomes in those with ILC.

• #19 Lobular breast cancer: incidence and genetic and non-genetic risk factors | Breast Cancer Research | Full Text

  https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-015-0546-7

  While most invasive breast cancers consist of carcinomas of the ductal type, about 10% are invasive lobular carcinomas. […] Invasive lobular carcinoma is more strongly associated with exposure to female hormones, and therefore its incidence is more subject to variation. […] This is illustrated by US figures during the 1987 to 2004 period: after 12 years of increases, breast cancer incidence declined steadily from 1999 to 2004, reflecting among other causes the decreasing use of menopausal hormone therapy, and these variations were stronger for invasive lobular than for invasive ductal carcinoma. […] Similarly, invasive lobular carcinoma is more strongly associated with early menarche, late menopause and late age at first birth. […] The risk of invasive lobular carcinoma is high in female mutation carriers, as about 50% are expected to develop the disease. Carriers must therefore undergo intensive breast cancer screening, with, for example, yearly magnetic resonance imaging and mammogram starting at age 30 years.

• #20 Lobular breast cancer: incidence and genetic and non-genetic risk factors | Breast Cancer Research | Full Text

  https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-015-0546-7

  While most invasive breast cancers consist of carcinomas of the ductal type, about 10% are invasive lobular carcinomas. […] Invasive lobular carcinoma is more strongly associated with exposure to female hormones, and therefore its incidence is more subject to variation. […] This is illustrated by US figures during the 1987 to 2004 period: after 12 years of increases, breast cancer incidence declined steadily from 1999 to 2004, reflecting among other causes the decreasing use of menopausal hormone therapy, and these variations were stronger for invasive lobular than for invasive ductal carcinoma. […] Similarly, invasive lobular carcinoma is more strongly associated with early menarche, late menopause and late age at first birth. […] The risk of invasive lobular carcinoma is high in female mutation carriers, as about 50% are expected to develop the disease. Carriers must therefore undergo intensive breast cancer screening, with, for example, yearly magnetic resonance imaging and mammogram starting at age 30 years.

• #21 Lobular breast cancer: incidence and genetic and non-genetic risk factors | Breast Cancer Research | Full Text

  https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-015-0546-7

  ILCs represent about 10% of invasive breast cancer cases. […] Studies conducted in the US indicated a 65% increase in the incidence of ILC between 1987 and 1999, while IDC rates increased by only 3% during the same period. […] However, after 1999, the age-adjusted incidence rates of both ILC and IDC steadily declined. […] It is likely that the decreasing use of MHT contributed to this decline, with an acceleration in use reduction from 2002 onwards associated with the publication of the Womens Health Initiative (WHI) trial results. […] A vast majority of these studies showed that MHT was more strongly associated with ILC than IDC. […] The high risk of ILC in females carrying a CDH1 mutation justifies personalized, intensive surveillance. […] The consensus 2010 CDH1 paper recommended that breast cancer surveillance be carried out within specific research protocols, and suggested annual magnetic resonance imaging (MRI) and mammogram starting at age 35 years. […] As ILC risk is close to the overall breast cancer risk seen in carriers of BRCA1/BRCA2 mutations, it seems reasonable to offer the same type of surveillance as a routine procedure, and start screening at age 30 years with annual MRI and mammogram.

• #22 A review of invasive lobular carcinoma of the breast: Should it be treated like invasive ductal carcinoma?

  https://oatext.com/A-review-of-invasive-lobular-carcinoma-of-the-breast-Should-it-be-treated-like-invasive-ductal-carcinoma.php

  ILC is the second most common breast cancer subtype accounting for about 10% of breast cancer cases. […] Most ILC are hormone receptor-positive and HER2 receptor negative, with up to 95% being estrogen receptor (ER) positive, and 70% being progesterone receptor (PR) positive. […] Several observational studies suggest that the relative risk of breast cancer for a post-menopausal woman on combined hormonal replacement therapy was higher for that of ILC than for IDC, with the relative risk of 1.5 for IDC compared to more than 2.0 for ILC. […] Familial clustering of ILC has also been reported. […] Even in the absence of inherited germline mutations in CDH1, the loss of E-cadherin expression is almost a universal occurrence in ILC, largely due to somatic CDH1 frameshift mutations and loss of heterozygosity or aberrant CDH1 promoter methylation.

• #23 Lobular breast cancer: incidence and genetic and non-genetic risk factors | Breast Cancer Research | Full Text

  https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-015-0546-7

  ILCs represent about 10% of invasive breast cancer cases. […] Studies conducted in the US indicated a 65% increase in the incidence of ILC between 1987 and 1999, while IDC rates increased by only 3% during the same period. […] However, after 1999, the age-adjusted incidence rates of both ILC and IDC steadily declined. […] It is likely that the decreasing use of MHT contributed to this decline, with an acceleration in use reduction from 2002 onwards associated with the publication of the Womens Health Initiative (WHI) trial results. […] A vast majority of these studies showed that MHT was more strongly associated with ILC than IDC. […] The high risk of ILC in females carrying a CDH1 mutation justifies personalized, intensive surveillance. […] The consensus 2010 CDH1 paper recommended that breast cancer surveillance be carried out within specific research protocols, and suggested annual magnetic resonance imaging (MRI) and mammogram starting at age 35 years. […] As ILC risk is close to the overall breast cancer risk seen in carriers of BRCA1/BRCA2 mutations, it seems reasonable to offer the same type of surveillance as a routine procedure, and start screening at age 30 years with annual MRI and mammogram.

• #24 Lobular breast cancer: incidence and genetic and non-genetic risk factors | Breast Cancer Research | Full Text

  https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-015-0546-7

  ILCs represent about 10% of invasive breast cancer cases. […] Studies conducted in the US indicated a 65% increase in the incidence of ILC between 1987 and 1999, while IDC rates increased by only 3% during the same period. […] However, after 1999, the age-adjusted incidence rates of both ILC and IDC steadily declined. […] It is likely that the decreasing use of MHT contributed to this decline, with an acceleration in use reduction from 2002 onwards associated with the publication of the Womens Health Initiative (WHI) trial results. […] A vast majority of these studies showed that MHT was more strongly associated with ILC than IDC. […] The high risk of ILC in females carrying a CDH1 mutation justifies personalized, intensive surveillance. […] The consensus 2010 CDH1 paper recommended that breast cancer surveillance be carried out within specific research protocols, and suggested annual magnetic resonance imaging (MRI) and mammogram starting at age 35 years. […] As ILC risk is close to the overall breast cancer risk seen in carriers of BRCA1/BRCA2 mutations, it seems reasonable to offer the same type of surveillance as a routine procedure, and start screening at age 30 years with annual MRI and mammogram.

• #25 Breast Cancer: Practice Essentials, Background, Anatomy

  https://emedicine.medscape.com/article/1947145-overview

  The reason for the decline has been extensively debated. Breast cancer rates decreased significantly after the reports from the Million Women Study and the Womens Health Initiative showing higher numbers of breast cancers in women using combination HRT with estrogen and progestin for menopausal symptoms. The near-immediate decrease in the use of combination HRT for that purpose has been widely accepted as a primary explanation for the decrease in breast cancer rates. […] The second observation noted by Jemal et al was that despite evidence for a plateau effect, screening saturation alone could not explain the dramatic declines or the pattern of decline. The decline in incidence was observed only for ER-positive tumors and not for ER-negative ones; these findings support the competing hypothesis that exposure to HRT as estrogen in combination with synthetic progesterone promoted the growth of undetected tumors.

• #26 Lobular breast cancer: incidence and genetic and non-genetic risk factors | Breast Cancer Research | Full Text

  https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-015-0546-7

  While most invasive breast cancers consist of carcinomas of the ductal type, about 10% are invasive lobular carcinomas. […] Invasive lobular carcinoma is more strongly associated with exposure to female hormones, and therefore its incidence is more subject to variation. […] This is illustrated by US figures during the 1987 to 2004 period: after 12 years of increases, breast cancer incidence declined steadily from 1999 to 2004, reflecting among other causes the decreasing use of menopausal hormone therapy, and these variations were stronger for invasive lobular than for invasive ductal carcinoma. […] Similarly, invasive lobular carcinoma is more strongly associated with early menarche, late menopause and late age at first birth. […] The risk of invasive lobular carcinoma is high in female mutation carriers, as about 50% are expected to develop the disease. Carriers must therefore undergo intensive breast cancer screening, with, for example, yearly magnetic resonance imaging and mammogram starting at age 30 years.

• #27 Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights

  https://www.mdpi.com/2072-6694/15/22/5491

  The most common driver mutations in ILC are CDH1, PIK3CA, FOXA1, PTEN, FGFR2, ERBB2, FGFR2 and ERBB3. CDH1 mutations are the most frequent mutations seen in ILC (in up to 65% of cases). E-cadherin, a 120 kDa transmembrane glycoprotein transcribed by the CDH1 gene, is central to lobular carcinoma pathogenesis. The IGF1 pathway is known for its association with breast cancer progression. Higher IGF1/2 expression and its receptor activation is seen in ILCs compared to ductal carcinomas. […] Mammography, which is a widespread screening tool in the detection of breast cancers, has its limitations in ILC owing to the diffuse nature of the tumor. The sensitivity varies widely from 30 to 83%. Ultrasound, which is not a routinely employed technique in mass breast screening, has shown a sensitivity ranging from 66–98% in detection of ILC and is used as an adjunct tool in the detection of ILC, especially in women with dense breasts. The most common presentation of ILCs on MRI is irregular or spiculated margins or a non-mass lesion. Magnetic resonance imaging (MRI) has been reported to reach near-perfect sensitivity rates (93–100%) in ILC detection and has higher accuracy rates while detecting synchronous and bilateral lesions.

• #28 Invasive Lobular Cancer (ILC) Melbourne, VIC | Radiotherapy Melbourne, VIC

  https://www.melbournebreastcancersurgery.com.au/breast-cancer/invasive-lobular-cancer-ilc.html

  Alcohol consumption, which is a known risk factor for all breast cancers, appears to have a greater impact on risk of invasive lobular carcinoma compared with invasive ductal carcinoma. […] Hereditary breast cancer is rare in patients with ILC (5%), but may be seen in families with hereditary diffuse gastric cancer syndrome, caused by a germline mutation in the tumour suppressor gene, CDH1. […] ILC otherwise accounts for a minority of cancers associated with known susceptibility genes, comprising less than 10% of cancers in patients with BRCA2 mutations, and less than 5% of cancers in patients with BRCA1 or TP53 mutations. […] The higher incidence of nodal disease at presentation in ILC has been well documented, and was also was observed in this study. […] The optimal imaging method for preoperative nodal staging in ILC has however not been clearly defined.

• #29 Pathology Outlines – Invasive lobular carcinoma classic

  https://www.pathologyoutlines.com/topic/breastmalignantlobularclassic.html

  Epidemiology […] – Comprises about 10% of invasive breast carcinomas (Breast Cancer Res 2015;17:37) […] – Most common special subtype of invasive breast carcinoma (Br J Cancer 2005;93:1046) […] – Only comprises 1% of male breast carcinomas (Breast Cancer (Dove Med Press) 2017;9:337) […] – Mean age of diagnosis is 63.4 years, higher than that for invasive breast carcinoma of no special type (Br J Cancer 2005;93:1046) […] – Endogenous (lower parity, younger age at menarche and later menopause) and exogenous (hormone replacement therapy and oral contraceptives) estrogen exposure increases risk (Breast Cancer Res 2015;17:37) […] – Alcohol consumption and obesity are risk factors, which may be mediated by increased levels of circulating estrogen […] – 60% lifetime risk in women with hereditary diffuse gastric cancer syndrome (germline CDH1 mutation) (J Med Genet 2010;47:436) […] – Under represented in breast carcinomas of BRCA1 carriers (2.2%) and similar proportion BRCA2 carriers (8.4%) (Cancer Epidemiol Biomarkers Prev 2012;21:134)

• #30 Invasive Lobular Cancer (ILC) Melbourne, VIC | Radiotherapy Melbourne, VIC

  https://www.melbournebreastcancersurgery.com.au/breast-cancer/invasive-lobular-cancer-ilc.html

  Alcohol consumption, which is a known risk factor for all breast cancers, appears to have a greater impact on risk of invasive lobular carcinoma compared with invasive ductal carcinoma. […] Hereditary breast cancer is rare in patients with ILC (5%), but may be seen in families with hereditary diffuse gastric cancer syndrome, caused by a germline mutation in the tumour suppressor gene, CDH1. […] ILC otherwise accounts for a minority of cancers associated with known susceptibility genes, comprising less than 10% of cancers in patients with BRCA2 mutations, and less than 5% of cancers in patients with BRCA1 or TP53 mutations. […] The higher incidence of nodal disease at presentation in ILC has been well documented, and was also was observed in this study. […] The optimal imaging method for preoperative nodal staging in ILC has however not been clearly defined.

• #31 Invasive Lobular Cancer (ILC) Melbourne, VIC | Radiotherapy Melbourne, VIC

  https://www.melbournebreastcancersurgery.com.au/breast-cancer/invasive-lobular-cancer-ilc.html

  Alcohol consumption, which is a known risk factor for all breast cancers, appears to have a greater impact on risk of invasive lobular carcinoma compared with invasive ductal carcinoma. […] Hereditary breast cancer is rare in patients with ILC (5%), but may be seen in families with hereditary diffuse gastric cancer syndrome, caused by a germline mutation in the tumour suppressor gene, CDH1. […] ILC otherwise accounts for a minority of cancers associated with known susceptibility genes, comprising less than 10% of cancers in patients with BRCA2 mutations, and less than 5% of cancers in patients with BRCA1 or TP53 mutations. […] The higher incidence of nodal disease at presentation in ILC has been well documented, and was also was observed in this study. […] The optimal imaging method for preoperative nodal staging in ILC has however not been clearly defined.

• #32 Pathology Outlines – Invasive lobular carcinoma classic

  https://www.pathologyoutlines.com/topic/breastmalignantlobularclassic.html

  Epidemiology […] – Comprises about 10% of invasive breast carcinomas (Breast Cancer Res 2015;17:37) […] – Most common special subtype of invasive breast carcinoma (Br J Cancer 2005;93:1046) […] – Only comprises 1% of male breast carcinomas (Breast Cancer (Dove Med Press) 2017;9:337) […] – Mean age of diagnosis is 63.4 years, higher than that for invasive breast carcinoma of no special type (Br J Cancer 2005;93:1046) […] – Endogenous (lower parity, younger age at menarche and later menopause) and exogenous (hormone replacement therapy and oral contraceptives) estrogen exposure increases risk (Breast Cancer Res 2015;17:37) […] – Alcohol consumption and obesity are risk factors, which may be mediated by increased levels of circulating estrogen […] – 60% lifetime risk in women with hereditary diffuse gastric cancer syndrome (germline CDH1 mutation) (J Med Genet 2010;47:436) […] – Under represented in breast carcinomas of BRCA1 carriers (2.2%) and similar proportion BRCA2 carriers (8.4%) (Cancer Epidemiol Biomarkers Prev 2012;21:134)

• #33 Lobular Research | UCSF Department of Surgery

  https://lobularbreastcancer.ucsf.edu/lobular-research-overview

  Invasive lobular carcinoma (ILC) is known to be a hormone receptor positive and HER2 receptor negative breast cancer. Our analysis showed that the characteristics of early stage (I-III) ILC can vary by socioeconomic status (SES, which we measured using education and income). In this cohort of over 200,000 patients with ILC in the National Cancer Database, we found that low SES was associated with fewer hormone positive and higher-grade tumors. […] We are interested in understanding the distribution and the clinical significance of ER/PR hormone receptor positivity in early-stage ILC. Overall, we know that ILC is typically regarded as strongly ER and PR positive and there is very little data that exists evaluating the spectrum of hormone receptor positivity in ILC. […] A recent analysis of the SEER database showed that racial/ethnic identity is associated with worse outcomes in those with ILC.

• #34 Surveillance Strategies After Primary Treatment for Patients with Invasive Lobular Carcinoma of the Breast: Method of Local Recurrence Detection After Breast-Conserving Surgery

  https://pmc.ncbi.nlm.nih.gov/articles/PMC11452458/

  Invasive lobular carcinoma (ILC) is the second most common subtype of breast cancer. Although mammography is known to have low sensitivity for ILC, there are no data to guide the optimal surveillance after treatment. We explored surveillance strategies after breast-conserving surgery (BCS) for ILC and determined the proportion of imaging-detected recurrences versus interval cancers. […] In this study of patients with recurrence after BCS for primary treatment of stage IIII ILC, we found that most local recurrences were not detected by surveillance mammography. These data support further investigation of supplemental imaging beyond mammography specifically for patients with ILC who undergo BCS. […] After completion of treatment for early-stage breast cancer, patients remain at risk for both local and distant recurrence. The magnitude of risk ranges from approximately 335% at 10 years depending on tumor biology, stage, and treatment type.

• #35

  https://link.springer.com/article/10.1245/s10434-024-15710-1

  Invasive lobular carcinoma (ILC) is the second most common subtype of breast cancer. Although mammography is known to have low sensitivity for ILC, there are no data to guide the optimal surveillance after treatment. We explored surveillance strategies after breast-conserving surgery (BCS) for ILC and determined the proportion of imaging-detected recurrences versus interval cancers. […] Most patients underwent routine mammographic surveillance (65.2%), with 19.6% having supplemental breast magnetic resonance imaging (MRI) and 15.2% having no surveillance. The interval cancer rate was significantly higher in the mammographic surveillance group compared with the MRI surveillance group (61.9% vs. 16.7%; p 0.001). […] In this study of patients with recurrence after BCS for primary treatment of stage IIII ILC, we found that most local recurrences were not detected by surveillance mammography. These data support further investigation of supplemental imaging beyond mammography specifically for patients with ILC who undergo BCS.

• #36 Invasive lobular carcinoma of the breast | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/invasive-lobular-carcinoma-of-the-breast?lang=us

  Invasive lobular carcinoma is the most common special type of invasive breast cancer after invasive breast carcinoma of no special type (invasive ductal carcinoma not otherwise specified). […] They represent 5-10% of all breast cancer. […] There is a greater rate of contralateral breast cancer in invasive lobular carcinoma compared with invasive carcinoma of no special type, with a 5-year rate of bilateral cancer of 8% (4% synchronous and 4% metachronous tumors). […] Invasive lobular carcinoma is more often multicentric and bilateral (10-15%). Therefore imaging evaluation of the contralateral breast is crucial. […] The sensitivity of mammography for the detection of Invasive lobular carcinoma reportedly ranges between 57-81%. […] Due to its propensity for multicentricity, breast MRI is usually recommended in many countries when histology of a lesion reveals invasive lobular carcinoma. […] Despite the difficulties of mammographic diagnosis and the propensity for multiplicity and bilaterality, the overall survival rate for patients with invasive lobular carcinoma of a given size and stage is believed to be slightly higher than for patients with invasive ductal carcinomas.

• #37 Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights

  https://www.mdpi.com/2072-6694/15/22/5491

  The most common driver mutations in ILC are CDH1, PIK3CA, FOXA1, PTEN, FGFR2, ERBB2, FGFR2 and ERBB3. CDH1 mutations are the most frequent mutations seen in ILC (in up to 65% of cases). E-cadherin, a 120 kDa transmembrane glycoprotein transcribed by the CDH1 gene, is central to lobular carcinoma pathogenesis. The IGF1 pathway is known for its association with breast cancer progression. Higher IGF1/2 expression and its receptor activation is seen in ILCs compared to ductal carcinomas. […] Mammography, which is a widespread screening tool in the detection of breast cancers, has its limitations in ILC owing to the diffuse nature of the tumor. The sensitivity varies widely from 30 to 83%. Ultrasound, which is not a routinely employed technique in mass breast screening, has shown a sensitivity ranging from 66–98% in detection of ILC and is used as an adjunct tool in the detection of ILC, especially in women with dense breasts. The most common presentation of ILCs on MRI is irregular or spiculated margins or a non-mass lesion. Magnetic resonance imaging (MRI) has been reported to reach near-perfect sensitivity rates (93–100%) in ILC detection and has higher accuracy rates while detecting synchronous and bilateral lesions.

• #38 Invasive Lobular Cancer (ILC) Melbourne, VIC | Radiotherapy Melbourne, VIC

  https://www.melbournebreastcancersurgery.com.au/breast-cancer/invasive-lobular-cancer-ilc.html

  Mammography and ultrasound are less reliable for the early detection of lobular breast cancer, which can lead to later detection, and a more advanced stage at diagnosis, although MRI may be better able to detect lobular carcinoma than mammography. […] The majority of ILC (68%) present as asymmetric densities or as masses with poorly defined margins, and a well-circumscribed mass is an uncommon mammographic presentation of ILC, seen in less than 1% of lobular tumours. […] American Joint Committee on Cancer TNM guidelines are used to stage all breast cancers, regardless of histology. […] Many studies, including a large Surveillance, Epidemiology, and End Results (SEER) registry analysis of 263,408 patients with IDC or ILC, report that patients with ILC are more likely to present with tumours measuring greater than 2cm at the time of diagnosis, as compared with IDC.

• #39 Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights

  https://www.mdpi.com/2072-6694/15/22/5491

  The most common driver mutations in ILC are CDH1, PIK3CA, FOXA1, PTEN, FGFR2, ERBB2, FGFR2 and ERBB3. CDH1 mutations are the most frequent mutations seen in ILC (in up to 65% of cases). E-cadherin, a 120 kDa transmembrane glycoprotein transcribed by the CDH1 gene, is central to lobular carcinoma pathogenesis. The IGF1 pathway is known for its association with breast cancer progression. Higher IGF1/2 expression and its receptor activation is seen in ILCs compared to ductal carcinomas. […] Mammography, which is a widespread screening tool in the detection of breast cancers, has its limitations in ILC owing to the diffuse nature of the tumor. The sensitivity varies widely from 30 to 83%. Ultrasound, which is not a routinely employed technique in mass breast screening, has shown a sensitivity ranging from 66–98% in detection of ILC and is used as an adjunct tool in the detection of ILC, especially in women with dense breasts. The most common presentation of ILCs on MRI is irregular or spiculated margins or a non-mass lesion. Magnetic resonance imaging (MRI) has been reported to reach near-perfect sensitivity rates (93–100%) in ILC detection and has higher accuracy rates while detecting synchronous and bilateral lesions.

• #40 Invasive lobular carcinoma of the breast | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/invasive-lobular-carcinoma-of-the-breast?lang=us

  Invasive lobular carcinoma is the most common special type of invasive breast cancer after invasive breast carcinoma of no special type (invasive ductal carcinoma not otherwise specified). […] They represent 5-10% of all breast cancer. […] There is a greater rate of contralateral breast cancer in invasive lobular carcinoma compared with invasive carcinoma of no special type, with a 5-year rate of bilateral cancer of 8% (4% synchronous and 4% metachronous tumors). […] Invasive lobular carcinoma is more often multicentric and bilateral (10-15%). Therefore imaging evaluation of the contralateral breast is crucial. […] The sensitivity of mammography for the detection of Invasive lobular carcinoma reportedly ranges between 57-81%. […] Due to its propensity for multicentricity, breast MRI is usually recommended in many countries when histology of a lesion reveals invasive lobular carcinoma. […] Despite the difficulties of mammographic diagnosis and the propensity for multiplicity and bilaterality, the overall survival rate for patients with invasive lobular carcinoma of a given size and stage is believed to be slightly higher than for patients with invasive ductal carcinomas.

• #41 Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights

  https://www.mdpi.com/2072-6694/15/22/5491

  The most common driver mutations in ILC are CDH1, PIK3CA, FOXA1, PTEN, FGFR2, ERBB2, FGFR2 and ERBB3. CDH1 mutations are the most frequent mutations seen in ILC (in up to 65% of cases). E-cadherin, a 120 kDa transmembrane glycoprotein transcribed by the CDH1 gene, is central to lobular carcinoma pathogenesis. The IGF1 pathway is known for its association with breast cancer progression. Higher IGF1/2 expression and its receptor activation is seen in ILCs compared to ductal carcinomas. […] Mammography, which is a widespread screening tool in the detection of breast cancers, has its limitations in ILC owing to the diffuse nature of the tumor. The sensitivity varies widely from 30 to 83%. Ultrasound, which is not a routinely employed technique in mass breast screening, has shown a sensitivity ranging from 66–98% in detection of ILC and is used as an adjunct tool in the detection of ILC, especially in women with dense breasts. The most common presentation of ILCs on MRI is irregular or spiculated margins or a non-mass lesion. Magnetic resonance imaging (MRI) has been reported to reach near-perfect sensitivity rates (93–100%) in ILC detection and has higher accuracy rates while detecting synchronous and bilateral lesions.

• #42 Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights

  https://www.mdpi.com/2072-6694/15/22/5491

  The most common driver mutations in ILC are CDH1, PIK3CA, FOXA1, PTEN, FGFR2, ERBB2, FGFR2 and ERBB3. CDH1 mutations are the most frequent mutations seen in ILC (in up to 65% of cases). E-cadherin, a 120 kDa transmembrane glycoprotein transcribed by the CDH1 gene, is central to lobular carcinoma pathogenesis. The IGF1 pathway is known for its association with breast cancer progression. Higher IGF1/2 expression and its receptor activation is seen in ILCs compared to ductal carcinomas. […] Mammography, which is a widespread screening tool in the detection of breast cancers, has its limitations in ILC owing to the diffuse nature of the tumor. The sensitivity varies widely from 30 to 83%. Ultrasound, which is not a routinely employed technique in mass breast screening, has shown a sensitivity ranging from 66–98% in detection of ILC and is used as an adjunct tool in the detection of ILC, especially in women with dense breasts. The most common presentation of ILCs on MRI is irregular or spiculated margins or a non-mass lesion. Magnetic resonance imaging (MRI) has been reported to reach near-perfect sensitivity rates (93–100%) in ILC detection and has higher accuracy rates while detecting synchronous and bilateral lesions.

• #43 Surveillance Strategies After Primary Treatment for Patients with Invasive Lobular Carcinoma of the Breast: Method of Local Recurrence Detection After Breast-Conserving Surgery

  https://pmc.ncbi.nlm.nih.gov/articles/PMC11452458/

  Invasive lobular carcinoma (ILC) is the second most common subtype of breast cancer. Although mammography is known to have low sensitivity for ILC, there are no data to guide the optimal surveillance after treatment. We explored surveillance strategies after breast-conserving surgery (BCS) for ILC and determined the proportion of imaging-detected recurrences versus interval cancers. […] In this study of patients with recurrence after BCS for primary treatment of stage IIII ILC, we found that most local recurrences were not detected by surveillance mammography. These data support further investigation of supplemental imaging beyond mammography specifically for patients with ILC who undergo BCS. […] After completion of treatment for early-stage breast cancer, patients remain at risk for both local and distant recurrence. The magnitude of risk ranges from approximately 335% at 10 years depending on tumor biology, stage, and treatment type.

• #44

  https://link.springer.com/article/10.1245/s10434-024-15710-1

  Invasive lobular carcinoma (ILC) is the second most common subtype of breast cancer. Although mammography is known to have low sensitivity for ILC, there are no data to guide the optimal surveillance after treatment. We explored surveillance strategies after breast-conserving surgery (BCS) for ILC and determined the proportion of imaging-detected recurrences versus interval cancers. […] Most patients underwent routine mammographic surveillance (65.2%), with 19.6% having supplemental breast magnetic resonance imaging (MRI) and 15.2% having no surveillance. The interval cancer rate was significantly higher in the mammographic surveillance group compared with the MRI surveillance group (61.9% vs. 16.7%; p 0.001). […] In this study of patients with recurrence after BCS for primary treatment of stage IIII ILC, we found that most local recurrences were not detected by surveillance mammography. These data support further investigation of supplemental imaging beyond mammography specifically for patients with ILC who undergo BCS.

• #45 Surveillance Strategies After Primary Treatment for Patients with Invasive Lobular Carcinoma of the Breast: Method of Local Recurrence Detection After Breast-Conserving Surgery

  https://pmc.ncbi.nlm.nih.gov/articles/PMC11452458/

  Of the 58 cases, the method of breast cancer surveillance after primary ILC treatment was known in 46 patients. Most patients (65.2%) underwent routine mammographic surveillance only, while 19.6% underwent supplemental imaging with breast MRI and 15.2% of patients received no surveillance imaging. […] Among those patients undergoing surveillance imaging, the interval cancer rate was 51.9%, meaning just over half of recurrences were detected clinically (patient symptom or physical examination) instead of on routine imaging. The interval cancer rate was significantly higher in the group having mammography alone compared with those having supplemental breast MRI (61.9% vs. 16.7%; p 0.0001). […] Overall, we found that for patients who undergo BCS after diagnosis of ILC, supplemental imaging surveillance with breast MRI is more common in younger women and is associated with significantly lower interval cancer rate compared with mammography alone. These findings suggest that surveillance MRI may have utility for those with a prior personal history of ILC, which should be validated in larger studies. […] Our study suggests that supplemental imaging for surveillance should be considered specifically for those after BCS for ILC, and questions the utility of routine mammography.

• #46 Surveillance Strategies After Primary Treatment for Patients with Invasive Lobular Carcinoma of the Breast: Method of Local Recurrence Detection After Breast-Conserving Surgery

  https://pmc.ncbi.nlm.nih.gov/articles/PMC11452458/

  Of the 58 cases, the method of breast cancer surveillance after primary ILC treatment was known in 46 patients. Most patients (65.2%) underwent routine mammographic surveillance only, while 19.6% underwent supplemental imaging with breast MRI and 15.2% of patients received no surveillance imaging. […] Among those patients undergoing surveillance imaging, the interval cancer rate was 51.9%, meaning just over half of recurrences were detected clinically (patient symptom or physical examination) instead of on routine imaging. The interval cancer rate was significantly higher in the group having mammography alone compared with those having supplemental breast MRI (61.9% vs. 16.7%; p 0.0001). […] Overall, we found that for patients who undergo BCS after diagnosis of ILC, supplemental imaging surveillance with breast MRI is more common in younger women and is associated with significantly lower interval cancer rate compared with mammography alone. These findings suggest that surveillance MRI may have utility for those with a prior personal history of ILC, which should be validated in larger studies. […] Our study suggests that supplemental imaging for surveillance should be considered specifically for those after BCS for ILC, and questions the utility of routine mammography.

• #47

  https://link.springer.com/article/10.1245/s10434-024-15710-1

  Invasive lobular carcinoma (ILC) is the second most common subtype of breast cancer. Although mammography is known to have low sensitivity for ILC, there are no data to guide the optimal surveillance after treatment. We explored surveillance strategies after breast-conserving surgery (BCS) for ILC and determined the proportion of imaging-detected recurrences versus interval cancers. […] Most patients underwent routine mammographic surveillance (65.2%), with 19.6% having supplemental breast magnetic resonance imaging (MRI) and 15.2% having no surveillance. The interval cancer rate was significantly higher in the mammographic surveillance group compared with the MRI surveillance group (61.9% vs. 16.7%; p 0.001). […] In this study of patients with recurrence after BCS for primary treatment of stage IIII ILC, we found that most local recurrences were not detected by surveillance mammography. These data support further investigation of supplemental imaging beyond mammography specifically for patients with ILC who undergo BCS.

• #48 Surveillance Strategies After Primary Treatment for Patients with Invasive Lobular Carcinoma of the Breast: Method of Local Recurrence Detection After Breast-Conserving Surgery

  https://pmc.ncbi.nlm.nih.gov/articles/PMC11452458/

  Of the 58 cases, the method of breast cancer surveillance after primary ILC treatment was known in 46 patients. Most patients (65.2%) underwent routine mammographic surveillance only, while 19.6% underwent supplemental imaging with breast MRI and 15.2% of patients received no surveillance imaging. […] Among those patients undergoing surveillance imaging, the interval cancer rate was 51.9%, meaning just over half of recurrences were detected clinically (patient symptom or physical examination) instead of on routine imaging. The interval cancer rate was significantly higher in the group having mammography alone compared with those having supplemental breast MRI (61.9% vs. 16.7%; p 0.0001). […] Overall, we found that for patients who undergo BCS after diagnosis of ILC, supplemental imaging surveillance with breast MRI is more common in younger women and is associated with significantly lower interval cancer rate compared with mammography alone. These findings suggest that surveillance MRI may have utility for those with a prior personal history of ILC, which should be validated in larger studies. […] Our study suggests that supplemental imaging for surveillance should be considered specifically for those after BCS for ILC, and questions the utility of routine mammography.

• #49

  https://link.springer.com/article/10.1245/s10434-024-15710-1

  Overall, we found that for patients who undergo BCS after diagnosis of ILC, supplemental imaging surveillance with breast MRI is more common in younger women and is associated with significantly lower interval cancer rate compared with mammography alone. These findings suggest that surveillance MRI may have utility for those with a prior personal history of ILC, which should be validated in larger studies. […] Our study suggests that supplemental imaging for surveillance should be considered specifically for those after BCS for ILC, and questions the utility of routine mammography.

• #50 Surveillance Strategies After Primary Treatment for Patients with Invasive Lobular Carcinoma of the Breast: Method of Local Recurrence Detection After Breast-Conserving Surgery

  https://pmc.ncbi.nlm.nih.gov/articles/PMC11452458/

  Of the 58 cases, the method of breast cancer surveillance after primary ILC treatment was known in 46 patients. Most patients (65.2%) underwent routine mammographic surveillance only, while 19.6% underwent supplemental imaging with breast MRI and 15.2% of patients received no surveillance imaging. […] Among those patients undergoing surveillance imaging, the interval cancer rate was 51.9%, meaning just over half of recurrences were detected clinically (patient symptom or physical examination) instead of on routine imaging. The interval cancer rate was significantly higher in the group having mammography alone compared with those having supplemental breast MRI (61.9% vs. 16.7%; p 0.0001). […] Overall, we found that for patients who undergo BCS after diagnosis of ILC, supplemental imaging surveillance with breast MRI is more common in younger women and is associated with significantly lower interval cancer rate compared with mammography alone. These findings suggest that surveillance MRI may have utility for those with a prior personal history of ILC, which should be validated in larger studies. […] Our study suggests that supplemental imaging for surveillance should be considered specifically for those after BCS for ILC, and questions the utility of routine mammography.

• #51

  https://link.springer.com/article/10.1245/s10434-024-15710-1

  Overall, we found that for patients who undergo BCS after diagnosis of ILC, supplemental imaging surveillance with breast MRI is more common in younger women and is associated with significantly lower interval cancer rate compared with mammography alone. These findings suggest that surveillance MRI may have utility for those with a prior personal history of ILC, which should be validated in larger studies. […] Our study suggests that supplemental imaging for surveillance should be considered specifically for those after BCS for ILC, and questions the utility of routine mammography.

• #52 Lobular breast cancer: incidence and genetic and non-genetic risk factors | Breast Cancer Research | Full Text

  https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-015-0546-7

  ILCs represent about 10% of invasive breast cancer cases. […] Studies conducted in the US indicated a 65% increase in the incidence of ILC between 1987 and 1999, while IDC rates increased by only 3% during the same period. […] However, after 1999, the age-adjusted incidence rates of both ILC and IDC steadily declined. […] It is likely that the decreasing use of MHT contributed to this decline, with an acceleration in use reduction from 2002 onwards associated with the publication of the Womens Health Initiative (WHI) trial results. […] A vast majority of these studies showed that MHT was more strongly associated with ILC than IDC. […] The high risk of ILC in females carrying a CDH1 mutation justifies personalized, intensive surveillance. […] The consensus 2010 CDH1 paper recommended that breast cancer surveillance be carried out within specific research protocols, and suggested annual magnetic resonance imaging (MRI) and mammogram starting at age 35 years. […] As ILC risk is close to the overall breast cancer risk seen in carriers of BRCA1/BRCA2 mutations, it seems reasonable to offer the same type of surveillance as a routine procedure, and start screening at age 30 years with annual MRI and mammogram.

• #53 Lobular breast cancer: incidence and genetic and non-genetic risk factors | Breast Cancer Research | Full Text

  https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-015-0546-7

  ILCs represent about 10% of invasive breast cancer cases. […] Studies conducted in the US indicated a 65% increase in the incidence of ILC between 1987 and 1999, while IDC rates increased by only 3% during the same period. […] However, after 1999, the age-adjusted incidence rates of both ILC and IDC steadily declined. […] It is likely that the decreasing use of MHT contributed to this decline, with an acceleration in use reduction from 2002 onwards associated with the publication of the Womens Health Initiative (WHI) trial results. […] A vast majority of these studies showed that MHT was more strongly associated with ILC than IDC. […] The high risk of ILC in females carrying a CDH1 mutation justifies personalized, intensive surveillance. […] The consensus 2010 CDH1 paper recommended that breast cancer surveillance be carried out within specific research protocols, and suggested annual magnetic resonance imaging (MRI) and mammogram starting at age 35 years. […] As ILC risk is close to the overall breast cancer risk seen in carriers of BRCA1/BRCA2 mutations, it seems reasonable to offer the same type of surveillance as a routine procedure, and start screening at age 30 years with annual MRI and mammogram.

• #54 International symposium shines a bright light on long-overlooked lobular | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/news/center-news/2024/10/international-symposium-shines-bright-light-lobular-breast-cancer.html

  Late metastatic recurrence is higher in ILC than in ductal/NST breast cancers, but there is no lobular-specific protocol for follow-up after early-stage treatment. […] Mammography is used for prevention screening in the U.S., but its inability to capture lobular especially in dense breast tissue has caused distrust, frustration and illness insecurity. […] Mammograms are simply inadequate for this subtype. […] Surveillance after treatment remains another fraught area, since lobular patients are often followed with the same type of imaging that failed to pick up their cancer in the first place. […] There is a lot of great technology in the pipeline but we need more and we also need to expand access to patients. […] Experts also called for more personalized approaches, especially with regard to endocrine or anti-hormone therapy, as well as more education about lobular’s relationship with HRT.

• #55 International symposium shines a bright light on long-overlooked lobular | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/news/center-news/2024/10/international-symposium-shines-bright-light-lobular-breast-cancer.html

  Late metastatic recurrence is higher in ILC than in ductal/NST breast cancers, but there is no lobular-specific protocol for follow-up after early-stage treatment. […] Mammography is used for prevention screening in the U.S., but its inability to capture lobular especially in dense breast tissue has caused distrust, frustration and illness insecurity. […] Mammograms are simply inadequate for this subtype. […] Surveillance after treatment remains another fraught area, since lobular patients are often followed with the same type of imaging that failed to pick up their cancer in the first place. […] There is a lot of great technology in the pipeline but we need more and we also need to expand access to patients. […] Experts also called for more personalized approaches, especially with regard to endocrine or anti-hormone therapy, as well as more education about lobular’s relationship with HRT.

• #56 New Demographic Statistics on Lobular Breast Cancer From NCI – The Lobular Breast Cancer Alliance

  https://lobularbreastcancer.org/new-demographic-statistics-on-lobular-breast-cancer-from-nci/

  Over the past number of months, Lobular Breast Cancer Alliance (LBCA) staff have been meeting with National Cancer Institute (NCI) staff to determine the most useful ways to show population based data for those diagnosed with invasive lobular carcinoma (ILC), also known as lobular breast cancer. […] NCI maintains the Surveillance, Epidemiology, and End Results (SEER) database, which provides information on cancer statistics in the United States. […] Through our collaboration with NCI, we have begun to generate reports on demographic and other available data of the ILC population. […] To put these statistics in context, we have asked NCI to provide the same statistics for invasive non-lobular breast cancers to serve as a comparison group. […] LBCA will update the statistics as they are updated in NCIs systems. Please note that there is a several-year lag in the data statistics that NCI releases in the SEER database due to the time intensive nature involved in collecting, reporting, and synthesizing these data on a national level.

• #57 New Demographic Statistics on Lobular Breast Cancer From NCI – The Lobular Breast Cancer Alliance

  https://lobularbreastcancer.org/new-demographic-statistics-on-lobular-breast-cancer-from-nci/

  Over the past number of months, Lobular Breast Cancer Alliance (LBCA) staff have been meeting with National Cancer Institute (NCI) staff to determine the most useful ways to show population based data for those diagnosed with invasive lobular carcinoma (ILC), also known as lobular breast cancer. […] NCI maintains the Surveillance, Epidemiology, and End Results (SEER) database, which provides information on cancer statistics in the United States. […] Through our collaboration with NCI, we have begun to generate reports on demographic and other available data of the ILC population. […] To put these statistics in context, we have asked NCI to provide the same statistics for invasive non-lobular breast cancers to serve as a comparison group. […] LBCA will update the statistics as they are updated in NCIs systems. Please note that there is a several-year lag in the data statistics that NCI releases in the SEER database due to the time intensive nature involved in collecting, reporting, and synthesizing these data on a national level.

• #58 New Demographic Statistics on Lobular Breast Cancer From NCI – The Lobular Breast Cancer Alliance

  https://lobularbreastcancer.org/new-demographic-statistics-on-lobular-breast-cancer-from-nci/

  Over the past number of months, Lobular Breast Cancer Alliance (LBCA) staff have been meeting with National Cancer Institute (NCI) staff to determine the most useful ways to show population based data for those diagnosed with invasive lobular carcinoma (ILC), also known as lobular breast cancer. […] NCI maintains the Surveillance, Epidemiology, and End Results (SEER) database, which provides information on cancer statistics in the United States. […] Through our collaboration with NCI, we have begun to generate reports on demographic and other available data of the ILC population. […] To put these statistics in context, we have asked NCI to provide the same statistics for invasive non-lobular breast cancers to serve as a comparison group. […] LBCA will update the statistics as they are updated in NCIs systems. Please note that there is a several-year lag in the data statistics that NCI releases in the SEER database due to the time intensive nature involved in collecting, reporting, and synthesizing these data on a national level.

• #59 New Demographic Statistics on Lobular Breast Cancer From NCI – The Lobular Breast Cancer Alliance

  https://lobularbreastcancer.org/new-demographic-statistics-on-lobular-breast-cancer-from-nci/

  Over the past number of months, Lobular Breast Cancer Alliance (LBCA) staff have been meeting with National Cancer Institute (NCI) staff to determine the most useful ways to show population based data for those diagnosed with invasive lobular carcinoma (ILC), also known as lobular breast cancer. […] NCI maintains the Surveillance, Epidemiology, and End Results (SEER) database, which provides information on cancer statistics in the United States. […] Through our collaboration with NCI, we have begun to generate reports on demographic and other available data of the ILC population. […] To put these statistics in context, we have asked NCI to provide the same statistics for invasive non-lobular breast cancers to serve as a comparison group. […] LBCA will update the statistics as they are updated in NCIs systems. Please note that there is a several-year lag in the data statistics that NCI releases in the SEER database due to the time intensive nature involved in collecting, reporting, and synthesizing these data on a national level.

• #60 New Demographic Statistics on Lobular Breast Cancer From NCI – The Lobular Breast Cancer Alliance

  https://lobularbreastcancer.org/new-demographic-statistics-on-lobular-breast-cancer-from-nci/

  Over the past number of months, Lobular Breast Cancer Alliance (LBCA) staff have been meeting with National Cancer Institute (NCI) staff to determine the most useful ways to show population based data for those diagnosed with invasive lobular carcinoma (ILC), also known as lobular breast cancer. […] NCI maintains the Surveillance, Epidemiology, and End Results (SEER) database, which provides information on cancer statistics in the United States. […] Through our collaboration with NCI, we have begun to generate reports on demographic and other available data of the ILC population. […] To put these statistics in context, we have asked NCI to provide the same statistics for invasive non-lobular breast cancers to serve as a comparison group. […] LBCA will update the statistics as they are updated in NCIs systems. Please note that there is a several-year lag in the data statistics that NCI releases in the SEER database due to the time intensive nature involved in collecting, reporting, and synthesizing these data on a national level.

• #61 Outcomes of Sentinel Lymph Node Dissection Alone vs. Axillary Lymph Node Dissection in Early Stage Invasive Lobular Carcinoma: A Retrospective Study of the Surveillance, Epidemiology and End Results (SEER) Database | PLOS One

  https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0089778

  The American College of Surgeons Oncology Group (ACOSOG) Z0011 trial demonstrated no difference in local-regional recurrence (LRR), disease-specific survival (DSS) or overall survival (OS) for sentinel lymph node dissection (SLND) and completion axillary lymph node dissection (ALND) among patients undergoing breast-conserving therapy for clinical T1T2, N0 breast cancer with 1 or 2 positive SLNs. […] Because ILC has a different pattern of metastases, frequently presenting as small foci requiring immunohistochemistry for detection, the applicability of ACOSOG Z0011 trial data to ILC patients is unclear. […] We identified all ILC patients in the Surveillance, Epidemiology, and End Results (SEER) database (19982009) who met the ACOSOG Z0011 eligibility criteria. […] The SEER database was used to identify 49,084 patients older than 18 years of age who had been treated for ILC from January 1998 to November 2009 using the International Classification of Diseases (ICD) code 8520/3.

• #62 Clinicopathological characteristics and survival outcomes of invasive lobular carcinoma in different races | Oncotarget

  https://www.oncotarget.com/article/19396/

  To investigate the clinicopathological characteristics and to determine whether there is a differential effect of race and examine survival outcomes according to race, 18,295 breast invasive lobular carcinoma (ILC) patients were identified in the Surveillance, Epidemiology, and End Result (SEER) database, which includes White patients (n=15,936), Black patients (n=1,451) and patients of other races (including American Indians/Alaskan Natives and Asian/Pacific Islanders) (n=908). […] The five-year overall survival (OS) and five-year breast cancer specific survival (BCSS) were worst in the Black patients among these patients (85.5%, 76.0% and 87.7%, P0.01; 91.1%, 84.4% and 91.6%, P0.01). […] Among these patients, the Black patients had the worst survival outcomes in five-year OS and BCSS outcomes (HR=1.35, 95% confidence interval (CI) :1.20-1.51, P0.01; HR=1.39, 95%CI:1.21-1.61, P0.01, respectively). […] In conclusion, this study revealed that the Black patients had worse five-year OS and BCSS than White and other race patients.

• #63 Lobular Research | UCSF Department of Surgery

  https://lobularbreastcancer.ucsf.edu/lobular-research-overview

  Invasive lobular carcinoma (ILC) is known to be a hormone receptor positive and HER2 receptor negative breast cancer. Our analysis showed that the characteristics of early stage (I-III) ILC can vary by socioeconomic status (SES, which we measured using education and income). In this cohort of over 200,000 patients with ILC in the National Cancer Database, we found that low SES was associated with fewer hormone positive and higher-grade tumors. […] We are interested in understanding the distribution and the clinical significance of ER/PR hormone receptor positivity in early-stage ILC. Overall, we know that ILC is typically regarded as strongly ER and PR positive and there is very little data that exists evaluating the spectrum of hormone receptor positivity in ILC. […] A recent analysis of the SEER database showed that racial/ethnic identity is associated with worse outcomes in those with ILC.

• #64 Lobular Research | UCSF Department of Surgery

  https://lobularbreastcancer.ucsf.edu/lobular-research-overview

  Invasive lobular carcinoma (ILC) is known to be a hormone receptor positive and HER2 receptor negative breast cancer. Our analysis showed that the characteristics of early stage (I-III) ILC can vary by socioeconomic status (SES, which we measured using education and income). In this cohort of over 200,000 patients with ILC in the National Cancer Database, we found that low SES was associated with fewer hormone positive and higher-grade tumors. […] We are interested in understanding the distribution and the clinical significance of ER/PR hormone receptor positivity in early-stage ILC. Overall, we know that ILC is typically regarded as strongly ER and PR positive and there is very little data that exists evaluating the spectrum of hormone receptor positivity in ILC. […] A recent analysis of the SEER database showed that racial/ethnic identity is associated with worse outcomes in those with ILC.

• #65 Invasive Lobular Cancer (ILC) Melbourne, VIC | Radiotherapy Melbourne, VIC

  https://www.melbournebreastcancersurgery.com.au/breast-cancer/invasive-lobular-cancer-ilc.html

  Mammography and ultrasound are less reliable for the early detection of lobular breast cancer, which can lead to later detection, and a more advanced stage at diagnosis, although MRI may be better able to detect lobular carcinoma than mammography. […] The majority of ILC (68%) present as asymmetric densities or as masses with poorly defined margins, and a well-circumscribed mass is an uncommon mammographic presentation of ILC, seen in less than 1% of lobular tumours. […] American Joint Committee on Cancer TNM guidelines are used to stage all breast cancers, regardless of histology. […] Many studies, including a large Surveillance, Epidemiology, and End Results (SEER) registry analysis of 263,408 patients with IDC or ILC, report that patients with ILC are more likely to present with tumours measuring greater than 2cm at the time of diagnosis, as compared with IDC.

• #66 Invasive Lobular Cancer (ILC) Melbourne, VIC | Radiotherapy Melbourne, VIC

  https://www.melbournebreastcancersurgery.com.au/breast-cancer/invasive-lobular-cancer-ilc.html

  Mammography and ultrasound are less reliable for the early detection of lobular breast cancer, which can lead to later detection, and a more advanced stage at diagnosis, although MRI may be better able to detect lobular carcinoma than mammography. […] The majority of ILC (68%) present as asymmetric densities or as masses with poorly defined margins, and a well-circumscribed mass is an uncommon mammographic presentation of ILC, seen in less than 1% of lobular tumours. […] American Joint Committee on Cancer TNM guidelines are used to stage all breast cancers, regardless of histology. […] Many studies, including a large Surveillance, Epidemiology, and End Results (SEER) registry analysis of 263,408 patients with IDC or ILC, report that patients with ILC are more likely to present with tumours measuring greater than 2cm at the time of diagnosis, as compared with IDC.

• #67 Outcomes of Sentinel Lymph Node Dissection Alone vs. Axillary Lymph Node Dissection in Early Stage Invasive Lobular Carcinoma: A Retrospective Study of the Surveillance, Epidemiology and End Results (SEER) Database | PLOS One

  https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0089778

  The American College of Surgeons Oncology Group (ACOSOG) Z0011 trial demonstrated no difference in local-regional recurrence (LRR), disease-specific survival (DSS) or overall survival (OS) for sentinel lymph node dissection (SLND) and completion axillary lymph node dissection (ALND) among patients undergoing breast-conserving therapy for clinical T1T2, N0 breast cancer with 1 or 2 positive SLNs. […] Because ILC has a different pattern of metastases, frequently presenting as small foci requiring immunohistochemistry for detection, the applicability of ACOSOG Z0011 trial data to ILC patients is unclear. […] We identified all ILC patients in the Surveillance, Epidemiology, and End Results (SEER) database (19982009) who met the ACOSOG Z0011 eligibility criteria. […] The SEER database was used to identify 49,084 patients older than 18 years of age who had been treated for ILC from January 1998 to November 2009 using the International Classification of Diseases (ICD) code 8520/3.

• #68 SEER Inquiry System – Question 20130174 Details

  https://seer.cancer.gov/seer-inquiry/inquiry-detail/20130174/

  The 4th Edition of the WHO Classification of Tumors of the Breast now describes five variants of invasive lobular carcinoma. These variants are solid type, alveolar, pleomorphic, tubulolobular, and mixed-type. […] WHO has not yet proposed new ICD-O codes be assigned to these variants. The upcoming solid tumor (MP/H) revisions will include instructions on coding these variants.

• #69 SEER Inquiry System – Question 20130174 Details

  https://seer.cancer.gov/seer-inquiry/inquiry-detail/20130174/

  The 4th Edition of the WHO Classification of Tumors of the Breast now describes five variants of invasive lobular carcinoma. These variants are solid type, alveolar, pleomorphic, tubulolobular, and mixed-type. […] WHO has not yet proposed new ICD-O codes be assigned to these variants. The upcoming solid tumor (MP/H) revisions will include instructions on coding these variants.

• #70 International symposium shines a bright light on long-overlooked lobular | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/news/center-news/2024/10/international-symposium-shines-bright-light-lobular-breast-cancer.html

  Invasive lobular carcinoma, or ILC, has been considered and clinically treated just like ductal for decades, despite its distinctive growth pattern (it usually grows in lines, not lumps), its imaging issues (it’s harder to find on scans) and its unique biology. […] Many diagnosed with lobular have never heard of it; it’s seldom mentioned even during Breast Cancer Awareness Month and until now, there’s been no pathological standards for its diagnosis. […] Awareness of lobular as a distinct subtype is not only important for patients and clinicians, it’s important for drug companies and for the wider scientific community. […] Many clinicians still equate ILC with ductal or NST breast cancer. […] Lobular comprises around 15% of all breast cancer diagnoses, yet many patients and clinicians aren’t aware of the key differences between it and the more common ductal or NST (no specific type) breast cancer.

• #71 International symposium shines a bright light on long-overlooked lobular | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/news/center-news/2024/10/international-symposium-shines-bright-light-lobular-breast-cancer.html

  Lobular tends to grow in lines, not lumps, thanks to a lack of a cellular glue known as E-cadherin, which is encoded by the CDH1 gene. […] Its web-like growth pattern makes it harder to find on physical exams and mammograms, especially in patients with dense breast tissue. […] When lobular spreads or metastasizes, it’s equally elusive, due to the way it grows and its tendency to spread to unusual and hard-to-scan sites like the gastrointestinal (GI) tract, the ovaries, or the peritoneum (or abdominal lining). […] Symptoms of metastatic ILC can be subtle and are often dismissed or misdiagnosed, especially when traditional scans remain clear. […] Unfortunately, lobular receives only around 1% of cancer research funding, per the LBCA. […] The lack of funding and lack of trials means there are no lobular-specific treatments, nor are there tailored treatments for its subtypes, such as classic, non-classic, pleomorphic and mixed.

• #72 International symposium shines a bright light on long-overlooked lobular | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/news/center-news/2024/10/international-symposium-shines-bright-light-lobular-breast-cancer.html

  Late metastatic recurrence is higher in ILC than in ductal/NST breast cancers, but there is no lobular-specific protocol for follow-up after early-stage treatment. […] Mammography is used for prevention screening in the U.S., but its inability to capture lobular especially in dense breast tissue has caused distrust, frustration and illness insecurity. […] Mammograms are simply inadequate for this subtype. […] Surveillance after treatment remains another fraught area, since lobular patients are often followed with the same type of imaging that failed to pick up their cancer in the first place. […] There is a lot of great technology in the pipeline but we need more and we also need to expand access to patients. […] Experts also called for more personalized approaches, especially with regard to endocrine or anti-hormone therapy, as well as more education about lobular’s relationship with HRT.

• #73 International symposium shines a bright light on long-overlooked lobular | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/news/center-news/2024/10/international-symposium-shines-bright-light-lobular-breast-cancer.html

  Invasive lobular carcinoma, or ILC, has been considered and clinically treated just like ductal for decades, despite its distinctive growth pattern (it usually grows in lines, not lumps), its imaging issues (it’s harder to find on scans) and its unique biology. […] Many diagnosed with lobular have never heard of it; it’s seldom mentioned even during Breast Cancer Awareness Month and until now, there’s been no pathological standards for its diagnosis. […] Awareness of lobular as a distinct subtype is not only important for patients and clinicians, it’s important for drug companies and for the wider scientific community. […] Many clinicians still equate ILC with ductal or NST breast cancer. […] Lobular comprises around 15% of all breast cancer diagnoses, yet many patients and clinicians aren’t aware of the key differences between it and the more common ductal or NST (no specific type) breast cancer.

• #74 International symposium shines a bright light on long-overlooked lobular | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/news/center-news/2024/10/international-symposium-shines-bright-light-lobular-breast-cancer.html

  Invasive lobular carcinoma, or ILC, has been considered and clinically treated just like ductal for decades, despite its distinctive growth pattern (it usually grows in lines, not lumps), its imaging issues (it’s harder to find on scans) and its unique biology. […] Many diagnosed with lobular have never heard of it; it’s seldom mentioned even during Breast Cancer Awareness Month and until now, there’s been no pathological standards for its diagnosis. […] Awareness of lobular as a distinct subtype is not only important for patients and clinicians, it’s important for drug companies and for the wider scientific community. […] Many clinicians still equate ILC with ductal or NST breast cancer. […] Lobular comprises around 15% of all breast cancer diagnoses, yet many patients and clinicians aren’t aware of the key differences between it and the more common ductal or NST (no specific type) breast cancer.

• #75 International symposium shines a bright light on long-overlooked lobular | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/news/center-news/2024/10/international-symposium-shines-bright-light-lobular-breast-cancer.html

  Lobular tends to grow in lines, not lumps, thanks to a lack of a cellular glue known as E-cadherin, which is encoded by the CDH1 gene. […] Its web-like growth pattern makes it harder to find on physical exams and mammograms, especially in patients with dense breast tissue. […] When lobular spreads or metastasizes, it’s equally elusive, due to the way it grows and its tendency to spread to unusual and hard-to-scan sites like the gastrointestinal (GI) tract, the ovaries, or the peritoneum (or abdominal lining). […] Symptoms of metastatic ILC can be subtle and are often dismissed or misdiagnosed, especially when traditional scans remain clear. […] Unfortunately, lobular receives only around 1% of cancer research funding, per the LBCA. […] The lack of funding and lack of trials means there are no lobular-specific treatments, nor are there tailored treatments for its subtypes, such as classic, non-classic, pleomorphic and mixed.

• #76 International symposium shines a bright light on long-overlooked lobular | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/news/center-news/2024/10/international-symposium-shines-bright-light-lobular-breast-cancer.html

  Lobular tends to grow in lines, not lumps, thanks to a lack of a cellular glue known as E-cadherin, which is encoded by the CDH1 gene. […] Its web-like growth pattern makes it harder to find on physical exams and mammograms, especially in patients with dense breast tissue. […] When lobular spreads or metastasizes, it’s equally elusive, due to the way it grows and its tendency to spread to unusual and hard-to-scan sites like the gastrointestinal (GI) tract, the ovaries, or the peritoneum (or abdominal lining). […] Symptoms of metastatic ILC can be subtle and are often dismissed or misdiagnosed, especially when traditional scans remain clear. […] Unfortunately, lobular receives only around 1% of cancer research funding, per the LBCA. […] The lack of funding and lack of trials means there are no lobular-specific treatments, nor are there tailored treatments for its subtypes, such as classic, non-classic, pleomorphic and mixed.

• #77 What is invasive lobular carcinoma? | MD Anderson Cancer Center

  https://www.mdanderson.org/cancerwise/What-is-invasive-lobular-carcinoma-8-insights-on-lobular-breast-cancer.h00-159539745.html

  Mammograms and ultrasounds also arent effective in detecting the cancer because of its cell growth pattern. […] Until MRI becomes more widely used, Im afraid that lobular cancer is going to be underdetected, Mouabbi says. […] There are trends that can help identify people are at higher risk for invasive lobular carcinoma. […] Individuals with a family member who has also been diagnosed with the disease are at a higher risk of the same diagnosis, Mouabbi says. […] To help identify lobular breast cancer early, Mouabbi urges patients who fall into these categories be monitored with an MRI rather than an ultrasound. […] Many patients with invasive lobular carcinoma receive the standard-of-care chemotherapy, but the comprehensive review showed there isnt much clinical benefit. […] There are other therapies for invasive lobular carcinoma, but theyre not widely used yet. […] Because of this, lobular breast cancer can be treated with endocrine therapy. […] Mouabbi hopes to open clinical trials at MD Anderson soon to investigate treating these cancers with immunotherapy. […] To define more personalized approaches, Mouabbi says its critical to conduct clinical trials specific to lobular breast cancer. […] If theres a clinical trial specific to lobular breast cancer, I urge patients to consider enrolling, Mouabbi says.

• #78 What is invasive lobular carcinoma? | MD Anderson Cancer Center

  https://www.mdanderson.org/cancerwise/What-is-invasive-lobular-carcinoma-8-insights-on-lobular-breast-cancer.h00-159539745.html

  Mammograms and ultrasounds also arent effective in detecting the cancer because of its cell growth pattern. […] Until MRI becomes more widely used, Im afraid that lobular cancer is going to be underdetected, Mouabbi says. […] There are trends that can help identify people are at higher risk for invasive lobular carcinoma. […] Individuals with a family member who has also been diagnosed with the disease are at a higher risk of the same diagnosis, Mouabbi says. […] To help identify lobular breast cancer early, Mouabbi urges patients who fall into these categories be monitored with an MRI rather than an ultrasound. […] Many patients with invasive lobular carcinoma receive the standard-of-care chemotherapy, but the comprehensive review showed there isnt much clinical benefit. […] There are other therapies for invasive lobular carcinoma, but theyre not widely used yet. […] Because of this, lobular breast cancer can be treated with endocrine therapy. […] Mouabbi hopes to open clinical trials at MD Anderson soon to investigate treating these cancers with immunotherapy. […] To define more personalized approaches, Mouabbi says its critical to conduct clinical trials specific to lobular breast cancer. […] If theres a clinical trial specific to lobular breast cancer, I urge patients to consider enrolling, Mouabbi says.

• #79 Invasive Lobular Carcinoma: Symptoms, Treatment, Research | BCRF

  https://www.bcrf.org/about-breast-cancer/invasive-lobular-carcinoma/

  Current research shows that MRI may be better able to detect lobular carcinoma than mammography, and new techniques are being developed, with several in clinical trials now. […] The majority of these cancers are hormone receptor (HR)positive, so endocrine (anti-hormone) therapies are typically administered for lobular breast cancer treatment. […] The lack of clinical trials specific to lobular breast cancer continues to be a major barrier to advancing treatments for patients with this disease. […] International collaborations to make data accessible globally and increase awareness of the unique nature of invasive lobular carcinoma are shaping research and clinical management of this breast cancer subtype.

• #80 International symposium shines a bright light on long-overlooked lobular | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/news/center-news/2024/10/international-symposium-shines-bright-light-lobular-breast-cancer.html

  Late metastatic recurrence is higher in ILC than in ductal/NST breast cancers, but there is no lobular-specific protocol for follow-up after early-stage treatment. […] Mammography is used for prevention screening in the U.S., but its inability to capture lobular especially in dense breast tissue has caused distrust, frustration and illness insecurity. […] Mammograms are simply inadequate for this subtype. […] Surveillance after treatment remains another fraught area, since lobular patients are often followed with the same type of imaging that failed to pick up their cancer in the first place. […] There is a lot of great technology in the pipeline but we need more and we also need to expand access to patients. […] Experts also called for more personalized approaches, especially with regard to endocrine or anti-hormone therapy, as well as more education about lobular’s relationship with HRT.

• #81 What is invasive lobular carcinoma? | MD Anderson Cancer Center

  https://www.mdanderson.org/cancerwise/What-is-invasive-lobular-carcinoma-8-insights-on-lobular-breast-cancer.h00-159539745.html

  Mammograms and ultrasounds also arent effective in detecting the cancer because of its cell growth pattern. […] Until MRI becomes more widely used, Im afraid that lobular cancer is going to be underdetected, Mouabbi says. […] There are trends that can help identify people are at higher risk for invasive lobular carcinoma. […] Individuals with a family member who has also been diagnosed with the disease are at a higher risk of the same diagnosis, Mouabbi says. […] To help identify lobular breast cancer early, Mouabbi urges patients who fall into these categories be monitored with an MRI rather than an ultrasound. […] Many patients with invasive lobular carcinoma receive the standard-of-care chemotherapy, but the comprehensive review showed there isnt much clinical benefit. […] There are other therapies for invasive lobular carcinoma, but theyre not widely used yet. […] Because of this, lobular breast cancer can be treated with endocrine therapy. […] Mouabbi hopes to open clinical trials at MD Anderson soon to investigate treating these cancers with immunotherapy. […] To define more personalized approaches, Mouabbi says its critical to conduct clinical trials specific to lobular breast cancer. […] If theres a clinical trial specific to lobular breast cancer, I urge patients to consider enrolling, Mouabbi says.

• #82 What is invasive lobular carcinoma? | MD Anderson Cancer Center

  https://www.mdanderson.org/cancerwise/What-is-invasive-lobular-carcinoma-8-insights-on-lobular-breast-cancer.h00-159539745.html

  Mammograms and ultrasounds also arent effective in detecting the cancer because of its cell growth pattern. […] Until MRI becomes more widely used, Im afraid that lobular cancer is going to be underdetected, Mouabbi says. […] There are trends that can help identify people are at higher risk for invasive lobular carcinoma. […] Individuals with a family member who has also been diagnosed with the disease are at a higher risk of the same diagnosis, Mouabbi says. […] To help identify lobular breast cancer early, Mouabbi urges patients who fall into these categories be monitored with an MRI rather than an ultrasound. […] Many patients with invasive lobular carcinoma receive the standard-of-care chemotherapy, but the comprehensive review showed there isnt much clinical benefit. […] There are other therapies for invasive lobular carcinoma, but theyre not widely used yet. […] Because of this, lobular breast cancer can be treated with endocrine therapy. […] Mouabbi hopes to open clinical trials at MD Anderson soon to investigate treating these cancers with immunotherapy. […] To define more personalized approaches, Mouabbi says its critical to conduct clinical trials specific to lobular breast cancer. […] If theres a clinical trial specific to lobular breast cancer, I urge patients to consider enrolling, Mouabbi says.

• #83 International symposium shines a bright light on long-overlooked lobular | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/news/center-news/2024/10/international-symposium-shines-bright-light-lobular-breast-cancer.html

  Invasive lobular carcinoma, or ILC, has been considered and clinically treated just like ductal for decades, despite its distinctive growth pattern (it usually grows in lines, not lumps), its imaging issues (it’s harder to find on scans) and its unique biology. […] Many diagnosed with lobular have never heard of it; it’s seldom mentioned even during Breast Cancer Awareness Month and until now, there’s been no pathological standards for its diagnosis. […] Awareness of lobular as a distinct subtype is not only important for patients and clinicians, it’s important for drug companies and for the wider scientific community. […] Many clinicians still equate ILC with ductal or NST breast cancer. […] Lobular comprises around 15% of all breast cancer diagnoses, yet many patients and clinicians aren’t aware of the key differences between it and the more common ductal or NST (no specific type) breast cancer.

• #84 International symposium shines a bright light on long-overlooked lobular | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/news/center-news/2024/10/international-symposium-shines-bright-light-lobular-breast-cancer.html

  Invasive lobular carcinoma, or ILC, has been considered and clinically treated just like ductal for decades, despite its distinctive growth pattern (it usually grows in lines, not lumps), its imaging issues (it’s harder to find on scans) and its unique biology. […] Many diagnosed with lobular have never heard of it; it’s seldom mentioned even during Breast Cancer Awareness Month and until now, there’s been no pathological standards for its diagnosis. […] Awareness of lobular as a distinct subtype is not only important for patients and clinicians, it’s important for drug companies and for the wider scientific community. […] Many clinicians still equate ILC with ductal or NST breast cancer. […] Lobular comprises around 15% of all breast cancer diagnoses, yet many patients and clinicians aren’t aware of the key differences between it and the more common ductal or NST (no specific type) breast cancer.

• #85 Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights

  https://www.mdpi.com/2072-6694/15/22/5491

  Endocrine therapy is the widely preferred therapeutic modality for hormone receptor-positive ILC. Early-stage ILC has shown to have a favorable response to neoadjuvant endocrine therapy (NAET), showing volume reduction in the tumor within a few months of therapy. Aromatase inhibitors take the lead over tamoxifen for ILC treatment, as seen in two phase 3 trials, Breast International Group (BIG) 1–98 trial and ABCSG-8 study, showing overall improved survival rates with aromatase inhibitors. […] In recent times, preclinical and clinical studies dedicated to ILC have increased and have displayed some interesting findings. However, the need of the hour is multicentric and multipopulation trials specific to ILC, which can unravel the biology of this disease in more detail.

• #86 Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights

  https://www.mdpi.com/2072-6694/15/22/5491

  Endocrine therapy is the widely preferred therapeutic modality for hormone receptor-positive ILC. Early-stage ILC has shown to have a favorable response to neoadjuvant endocrine therapy (NAET), showing volume reduction in the tumor within a few months of therapy. Aromatase inhibitors take the lead over tamoxifen for ILC treatment, as seen in two phase 3 trials, Breast International Group (BIG) 1–98 trial and ABCSG-8 study, showing overall improved survival rates with aromatase inhibitors. […] In recent times, preclinical and clinical studies dedicated to ILC have increased and have displayed some interesting findings. However, the need of the hour is multicentric and multipopulation trials specific to ILC, which can unravel the biology of this disease in more detail.

Zobacz więcej